Article Text

PDF
Research paper
Olfactory impairment in familial ataxias
  1. Mariana Moscovich1,2,3,
  2. Renato Puppi Munhoz1,3,
  3. Helio A Teive1,
  4. Salmo Raskin4,
  5. Margarete de J Carvalho5,
  6. Egberto R Barbosa5,
  7. Ronald Ranvaud5,6,
  8. Jilin Liu2,
  9. Karen McFarland2,
  10. Tetsuo Ashizawa2,
  11. Andrew J Lees7,
  12. Laura Silveira-Moriyama7,8
  1. 1Department of Neurology, Hospital de Clínicas, Federal University of Paraná, Curitiba-PR, Brazil
  2. 2Department of Neurology, University of Florida, Center for Movement Disorders & Neurorestoration, McKnight Brain Institute, Gainesville, Florida, USA
  3. 3Department of Neurology, Pontifical Catholic University of Parana, Curitiba, Parana, Brazil
  4. 4Core for Advanced Molecular Investigation, Graduate Program in Health Sciences, Center for Biological and Health Sciences, Pontifical Catholic University of Paraná Curitiba, Parana, Brazil
  5. 5Department of Neurology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
  6. 6Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
  7. 7Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK
  8. 8Department of Neurology, University of Campinas, UNICAMP, Brazil
  1. Correspondence to Dr Laura Silveira-Moriyama, Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, 1 Wakefield St, London WC1N 1PJ, UK; l.moriyama{at}ion.ucl.ac.uk

Abstract

The main clinical manifestations of the spinocerebellar ataxias (SCAs) result from the involvement of the cerebellum and its connections. Cerebellar activity has been consistently observed in functional imaging studies of olfaction, but the anatomical pathways responsible for this connection have not yet been elucidated. Previous studies have demonstrated olfactory deficit in SCA2, Friedreich's ataxia and in small groups of ataxia of diverse aetiology. The authors used a validated version of the 16-item smell identification test from Sniffin' Sticks (SS-16) was used to evaluate 37 patients with genetically determined autosomal dominant ataxia, and 31 with familial ataxia of unknown genetic basis. This data was also compared with results in 106 Parkinson's disease patients and 218 healthy controls. The SS-16 score was significantly lower in ataxia than in the control group (p<0.001, 95% CI for β=0.55 to 1.90) and significantly higher in ataxia than in Parkinson's disease (p<0.001, 95% CI for β=−4.58 to −3.00) when adjusted for age (p=0.001, 95% CI for β=−0.05 to −0.01), gender (p=0.19) and history of tobacco use (p=0.41). When adjusted for general cognitive function, no significant difference was found between the ataxia and control groups. This study confirms previous findings of mild hyposmia in ataxia, and further suggests this may be due to general cognitive deficits rather than specific olfactory problems.

  • Movement disorders
  • smell
  • cerebellar ataxia
  • cerebellar degeneration
  • cognition

Statistics from Altmetric.com

Footnotes

  • Linked article 303136.

  • Funding This work was funded by the Reta Lila Weston Trust for Medical Research. Dr Laura Silveira-Moriyama is beneficiary of a Reta Lila Weston Fellowship, receives a grant from Parkinson's UK, and travel grant from UCB and Teva. Dr Moscovich reports no disclosures. Dr Munhoz reports no disclosures. Dr Ashizawa is funded by NINDS grant RC1NS068897, National Ataxia Foundation, Marigold Foundation. Dr Teive received personal compensation for educational activities with Allergan, Boehringer, Ingelheim, Ipsen, Novartis, and Roche, and serves as an editorial board member of Parkinsonism and Related Disorders, Journal of Neurology Research, Parkinson's Disease, Current Neurology and Neuroscience Reports, and Arquivos de Neuropsiquiatria. Dr Carvalho reports no disclosures. Dr Raskin reports no disclosure. Liu reports no disclosure. Dr Lees is funded by PSP Association, Weston Trust - The Reta Lila Howard Foundation grant, is a member consultant of Genus, advisory board of Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, Roche and received honoraria from Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, Roche. Dr Barbosa received personal compensation for educational activities from Boehringer- Ingelheim. Dr Ranvaud reports no disclosure. Dr McFarland reports no disclosure.

  • Competing interests None.

  • Ethics approval Ethics committee at the Federal University of Parana General Hospital.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editorial commentary
    Henry Houlden